Novel Treatments for Idiopathic Pulmonary Fibrosis

被引：10

作者：

Spagnolo, Paolo ^{[1
,2
]}

机构：

[1] Med Univ Clin, Canton Hosp Baselland, CH-4410 Liestal, Switzerland

[2] Univ Basel, Liestal, Switzerland

来源：

AMERICAN JOURNAL OF MEDICINE | 2015年 / 128卷 / 05期

关键词：

PIRFENIDONE; MORTALITY; SURVIVAL; TRIALS;

D O I：

10.1016/j.amjmed.2015.01.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：447 / 449

页数：3

共 16 条

[1]

[Anonymous], COCHRANE DATABASE SY

[2] Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis [J].

Chaudhary, N. I. ;

Roth, G. J. ;

Hilberg, F. ;

Mueller-Ouernheim, J. ;

Prasse, A. ;

Zissel, G. ;

Schnapp, A. ;

Park, J. E. .

EUROPEAN RESPIRATORY JOURNAL, 2007, 29 (05) :976-985

[3] Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis [J].

Collard, HR ;

King, TE ;

Bartelson, BB ;

Vourlekis, JS ;

Schwarz, MI ;

Brown, KK .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (05) :538-542

[4] Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis [J].

du Bois, Roland M. ;

Weycker, Derek ;

Albera, Carlo ;

Bradford, Williamson Z. ;

Costabel, Ulrich ;

Kartashov, Alex ;

Lancaster, Lisa ;

Noble, Paul W. ;

Raghu, Ganesh ;

Sahn, Steven A. ;

Szwarcberg, Javier ;

Thomeer, Michiel ;

Valeyre, Dominique ;

King, Talmadge E., Jr. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 184 (04) :459-466

[5] MUC5B Promoter Polymorphism and Interstitial Lung Abnormalities [J].

Hunninghake, Gary M. ;

Hatabu, Hiroto ;

Okajima, Yuka ;

Gao, Wei ;

Dupuis, Josee ;

Latourelle, Jeanne C. ;

Nishino, Mizuki ;

Araki, Tetsuro ;

Zazueta, Oscar E. ;

Kurugol, Sila ;

Ross, James C. ;

Estepar, Raul San Jose ;

Murphy, Elissa ;

Steele, Mark P. ;

Loyd, James E. ;

Schwarz, Marvin I. ;

Fingerlin, Tasha E. ;

Rosas, Ivan O. ;

Washko, George R. ;

O'Connor, George T. ;

Schwartz, David A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (23) :2192-2200

[6] A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis [J].

King, Talmadge E., Jr. ;

Bradford, Williamson Z. ;

Castro-Bernardini, Socorro ;

Fagan, Elizabeth A. ;

Glaspole, Ian ;

Glassberg, Marilyn K. ;

Gorina, Eduard ;

Hopkins, Peter M. ;

Kardatzke, David ;

Lancaster, Lisa ;

Lederer, David J. ;

Nathan, Steven D. ;

Pereira, Carlos A. ;

Sahn, Steven A. ;

Sussman, Robert ;

Swigris, Jeffrey J. ;

Noble, Paul W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (22) :2083-2092

[7] All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis Implications for the Design and Execution of Clinical Trials [J].

King, Talmadge E., Jr. ;

Albera, Carlo ;

Bradford, Williamson Z. ;

Costabel, Ulrich ;

du Bois, Roland M. ;

Leff, Jonathan A. ;

Nathan, Steven D. ;

Sahn, Steven A. ;

Valeyre, Dominique ;

Noble, Paul W. .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189 (07) :825-831

[8] Idiopathic pulmonary fibrosis [J].

King, Talmadge E., Jr. ;

Pardo, Annie ;

Selman, Moises .

LANCET, 2011, 378 (9807) :1949-1961

[9] The rising incidence of idiopathic pulmonary fibrosis in the UK [J].

Navaratnam, V. ;

Fleming, K. M. ;

West, J. ;

Smith, C. J. P. ;

Jenkins, R. G. ;

Fogarty, A. ;

Hubbard, R. B. .

THORAX, 2011, 66 (06) :462-467

[10] Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials [J].

Noble, Paul W. ;

Albera, Carlo ;

Bradford, Williamson Z. ;

Costabel, Ulrich ;

Glassberg, Marilyn K. ;

Kardatzke, David ;

King, Talmadge E., Jr. ;

Lancaster, Lisa ;

Sahn, Steven A. ;

Szwarcberg, Javier ;

Valeyre, Dominique ;

du Bois, Roland M. .

LANCET, 2011, 377 (9779) :1760-1769

← 1 2 →